Skip to main
MNKD

MannKind (MNKD) Stock Forecast & Price Target

MannKind (MNKD) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MannKind Corporation's continued advancement of its orphan lung pipeline positions the company for long-term diversification and growth, underscoring its strategic focus on expanding revenue streams. The management's commitment to enhancing education and marketing efforts, particularly through targeted campaigns for healthcare professionals, may further drive uptake of its inhaled therapeutic products. Additionally, with positive patient feedback on Tyvaso DPI and its market share growth, alongside the promising potential of Furoscix, MannKind is well-positioned to capitalize on emerging opportunities in the pharmaceutical landscape.

Bears say

MannKind Corp's stock outlook remains negative due to concerns over increased competition, particularly following the approval of a competitor's product, which influenced a significant share price decline. The potential for challenges to the company's intellectual property and the possibility of negative trial results raises doubts about the timely commercialization of their therapies, further weakening market confidence. Additionally, the presence of well-capitalized rivals with established products threatens to diminish MannKind's market share and pricing power in key therapeutic areas.

MannKind (MNKD) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MannKind (MNKD) Forecast

Analysts have given MannKind (MNKD) a Buy based on their latest research and market trends.

According to 6 analysts, MannKind (MNKD) has a Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MannKind (MNKD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.